ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category

Rhea-AI Summary

ChromaDex Corp. (NASDAQ:CDXC) has been named to the Inc. 2024 Best in Business list in the Health Products category, recognizing its contributions to the industry through NAD+ research and healthy aging products. The company's portfolio includes Tru Niagen®, a dietary supplement, and the new Niagen IV, both featuring patented nicotinamide riboside (NR), their high-quality NAD+ precursor. This recognition by Inc. magazine acknowledges companies that have achieved significant milestones and demonstrated exceptional execution in their core business.

Positive

• Recognition in Inc. 2024 Best in Business list strengthens market position
• Portfolio expansion with new pharmaceutical-grade Niagen IV product

Negative

• None.

LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ:CDXC) proudly announces its inclusion on the Inc. 2024 Best in Business list in the Health Products category. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made an impact on their industries and society at large.

This recognition underscores ChromaDex's industry-leading NAD+ research and its expanding portfolio of healthy aging products featuring Niagen^® (patented nicotinamide riboside or NR), the most efficient and high-quality NAD+ precursor. Such products include the direct-to-consumer dietary supplement, Tru Niagen^®, and the newly unveiled pharmaceutical-grade Niagen IV.

“Our mission is to help people around the world to age better, and this honor reflects the progress we’re making toward achieving that goal,” said ChromaDex CEO and Founder of Tru Niagen, Rob Fried.

The Inc. Best in Business list recognizes companies that, through exceptional execution, have achieved significant milestones and core business wins. Best in Business can be found online at inc.com/best-in-business and will be in the upcoming winter print edition of Inc. magazine.

“For over 40 years Inc. has been committed to recognizing America’s most dynamic businesses and honoring the great work they do. These businesses have had a profound impact on their industries, solving important problems, and shaping the future of business in ways that will have lasting effects,” says Inc. editor-in-chief Mike Hofman.

For additional information on ChromaDex and the science behind Niagen, please visit www.chromadex.com.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to product development. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

About ChromaDex:

ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality.

Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.

Niagen^® is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen^®, the number one healthy-aging NAD+ supplement in the United States^†. Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com). ChromaDex supplies pharmaceutical-grade Niagen^® to U.S. FDA-registered 503B outsourcing facilities, which compound and distribute intravenous and injectable Niagen^® for clinics. These pharmaceutical-grade Niagen^® products, known as Niagen IV and Niagen injections, are available exclusively at clinics with a prescription (www.niagenplus.com).

ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, where copies of press releases, news, and financial information are regularly published.

^†Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

About Inc.

Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of our community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating our future. Inc.'s award-winning work achieves a monthly brand footprint of more than 40 million across a variety of channels, including events, digital, print, video, podcasts, newsletters, and social media. Its proprietary Inc. 5000 list, produced every year since its launch as the Inc. 100 in 1982, analyzes company data to rank the fastest-growing privately held businesses in the United States. The recognition that comes with inclusion on this and other prestigious Inc. lists, such as Female Founders and Power Partners, gives the founders of top businesses the opportunity to engage with an exclusive community of their peers, and credibility that helps them drive sales and recruit talent. For more information, visit www.inc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241203087239/en/

ChromaDex Media Contact:

Kendall Knysch, Senior Director of Media Relations & Partnerships

310-388-6706 ext. 689

kendall.knysch@chromadex.com

ChromaDex Investor Relations Contact:

Ben Shamsian

Lytham Partners

646-829-9701

shamsian@lythampartners.com

Source: ChromaDex Corporation

FAQ

What award did ChromaDex (CDXC) receive in 2024?

ChromaDex was named to the Inc. 2024 Best in Business list in the Health Products category.

What are the main products in ChromaDex's (CDXC) portfolio?

ChromaDex's main products include Tru Niagen, a direct-to-consumer dietary supplement, and the newly launched pharmaceutical-grade Niagen IV, both featuring patented nicotinamide riboside (NR).

What is the key ingredient in ChromaDex's (CDXC) products?

The key ingredient is Niagen (patented nicotinamide riboside or NR), which is an NAD+ precursor.